Dr Rabinder Buttar Admitted into Strathclyde University's UK Academy
News Dec 11, 2015
Dr Buttar was admitted into Strathclyde University's UK Academy for Distinguished Entrepreneurs at the Strathclyde Enterprise Awards, held on 24th November at the Science Centre in Glasgow, for her work in establishing and building the global clinical research organization ClinTec International.
Strathclyde University's Academy for Distinguished Entrepreneurs Hall of Fame recognizes global entrepreneurs such as John Logie Baird the inventor of the world’s first working television and Dr James “Paraffin” Young who thrived by selling paraffin oil and lamps to countries around the world. The ceremony was hosted by BBC TV Presenter Sally Magnuson alongside entrepreneur Chris Van der Kyul, the developer of blockbuster video games Minecraft as a keynote speaker.
Other new entrants to the Academy included the inventor of the daily disposable contact lenses, Chairman of Daysoft Mr Ron Hamilton, and Mr John Neill the CEO of Unipart Group, an organization offering consulting and logistics services.
Strathclyde University is nationally recognized as a top UK grade and outstanding entrepreneurial University according to Times Higher Education 2015, and recently invested in a £89 million Technology and Innovation Centre which was opened by Her Majesty, the Queen and HRH Prince Phillip.
Dr Buttar said "I am proud and honoured to be recognized as a distinguished entrepreneur by this top UK University - a place of great learning that I am extremely fond of and where more than 20 years ago I was awarded a Ph.D. Degree in Immunology, developing novel monoclonal antibodies as new vaccines. I am grateful for the University and particularly Professor WH Stimson, to have given me a solid education on which to build my career in clinical research and to have ignited the entrepreneurial spark. This has enabled me to build ClinTec International from start to a globally respected clinical research organization operating in over 50 countries worldwide. I am pleased to see the next generation of budding entrepreneurs with their amazing spin out companies receiving their awards at this event and wish them much success on their exciting industrial journey."
Speaking at the awards dinner, Professor Sir Jim McDonald, Principal and Vice-Chancellor of the University of Strathclyde, said: “We are proud of the thriving and supportive community we have nurtured at Strathclyde, which spans the entrepreneurial lifecycle from undergraduate students with an interest in enterprise, to some of Strathclyde’s most successful entrepreneurs. Through these awards we show how we are instilling our innovative ethos throughout our student, alumni and research communities, to ensure our teaching and research benefit not only this University, but Scotland, the UK, and the rest of the world.”
Dr Rabinder Buttar who has been named as a top 10 practising entrepreneurial scientist in Britain by the British Science Council and received the Business Women of the Year 2015 Award (Glasgow Awards - People Make Glasgow), founded ClinTec International over 18 years ago. She is continuing to drive this privately owned business as it is recognized as the Best CRO in the UK.
ClinTec International has become a globally respected clinical research organization, with clients who include 7 of the world's top 10 multinational pharmaceutical companies, leading Japanese pharmaceutical companies as well as innovative smaller biotech companies. ClinTec International provides customized clinical research solutions and talented personnel in over 50 countries worldwide to progress drug development in a fast, flexible and focused way.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE